Monopar Therapeutics(MNPR) - 2025 Q2 - Quarterly Results

Filing Information Provides essential identification details for Monopar Therapeutics Inc., including its registration, securities, and company status Registrant Information Details Monopar Therapeutics Inc.'s fundamental identification, including incorporation state, principal offices, and contact information - Registrant: MONOPAR THERAPEUTICS INC.[2] - State of Incorporation: Delaware[3] - Principal Executive Offices: 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091[3] Securities Registered Lists Monopar Therapeutics Inc.'s Common Stock registered under Section 12(b), including its trading symbol and exchange Registered Securities | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :--------------------------------------- | | Common Stock, $0.001 par value | MNPR | The Nasdaq Stock Market LLC (Nasdaq Capital Market) | Emerging Growth Company Status Indicates that Monopar Therapeutics Inc. is not an emerging growth company - Monopar Therapeutics Inc. is not an emerging growth company[5] Item 2.02 Results of Operations and Financial Condition Reports the announcement of Monopar Therapeutics Inc.'s financial results for the second quarter ended June 30, 2025 Announcement of Financial Results Monopar Therapeutics Inc. announced Q2 2025 financial results via an August 12, 2025 press release, furnished but not legally "filed" - Monopar Therapeutics Inc. issued a press release on August 12, 2025, announcing financial results for the second quarter ended June 30, 2025[6] - A copy of the press release is attached as Exhibit 99.1[6] - The information in this item and exhibit is furnished and not deemed 'filed' under Section 18 of the Securities Exchange Act of 1934[7] Item 9.01 Financial Statements and Exhibits Provides a comprehensive list of financial statements and exhibits accompanying the filing Exhibits List Lists all exhibits accompanying the Form 8-K filing, including the press release and interactive data file Exhibits | Exhibit No. | Description | | :------------ | :---------------------------------------------------- | | 99.1 | Press Release Dated August 12, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | Signature Confirms the official authorization and signatory details for the filed report Authorization and Signatory The report is duly signed on behalf of Monopar Therapeutics Inc. by its Chief Financial Officer, Quan Vu, confirming authorization - The report was signed on August 12, 2025[12] - Signatory: Quan Vu, Chief Financial Officer of Monopar Therapeutics Inc.[12]